209 related articles for article (PubMed ID: 36729270)
1. A Pilot Study to Develop Paraneoplastic Cerebellar Degeneration Mouse Model.
Faure F; Yshii L; Renno T; Coste I; Joubert B; Desestret V; Liblau R; Honnorat J
Cerebellum; 2024 Feb; 23(1):181-196. PubMed ID: 36729270
[TBL] [Abstract][Full Text] [Related]
2. Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity.
Panja D; Vedeler CA; Schubert M
Neuropathol Appl Neurobiol; 2019 Feb; 45(2):141-156. PubMed ID: 29679372
[TBL] [Abstract][Full Text] [Related]
3. CDR2 and CDR2L line blot performance in PCA-1/anti-Yo paraneoplastic autoimmunity.
Vorasoot N; Scharf M; Miske R; Thakolwiboon S; Dubey D; Mills JR; Pittock SJ; Zekeridou A; Ott A; McKeon A
Front Immunol; 2023; 14():1265797. PubMed ID: 37841252
[TBL] [Abstract][Full Text] [Related]
4. Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.
Yshii L; Bost C; Liblau R
Front Immunol; 2020; 11():991. PubMed ID: 32655545
[TBL] [Abstract][Full Text] [Related]
5. CDR2L Is the Major Yo Antibody Target in Paraneoplastic Cerebellar Degeneration.
Kråkenes T; Herdlevaer I; Raspotnig M; Haugen M; Schubert M; Vedeler CA
Ann Neurol; 2019 Aug; 86(2):316-321. PubMed ID: 31148214
[TBL] [Abstract][Full Text] [Related]
6. A cerebellar degeneration-related protein 2-like cell-based assay for anti-Yo detection in patients with paraneoplastic cerebellar degeneration.
Erikstad KI; Herdlevaer I; Peter E; Haugen M; Totland C; Vedeler C
Eur J Neurol; 2023 Jun; 30(6):1727-1733. PubMed ID: 36912432
[TBL] [Abstract][Full Text] [Related]
7. The Discovery of Anti-Yo (Anti-PCA1) Antibody in Patients with Paraneoplastic Cerebellar Degeneration: Opening a Window into Autoimmune Neurological Disease.
Greenlee JE; Brashear HR
Cerebellum; 2023 Aug; 22(4):531-533. PubMed ID: 35881322
[TBL] [Abstract][Full Text] [Related]
8. CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration.
Eichler TW; Totland C; Haugen M; Qvale TH; Mazengia K; Storstein A; Haukanes BI; Vedeler CA
PLoS One; 2013; 8(6):e66002. PubMed ID: 23823982
[TBL] [Abstract][Full Text] [Related]
9. Anti-Yo antibody uptake and interaction with its intracellular target antigen causes Purkinje cell death in rat cerebellar slice cultures: a possible mechanism for paraneoplastic cerebellar degeneration in humans with gynecological or breast cancers.
Greenlee JE; Clawson SA; Hill KE; Wood B; Clardy SL; Tsunoda I; Carlson NG
PLoS One; 2015; 10(4):e0123446. PubMed ID: 25885452
[TBL] [Abstract][Full Text] [Related]
10. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice.
Tanaka K; Tanaka M; Igarashi S; Onodera O; Miyatake T; Tsuji S
Clin Neurol Neurosurg; 1995 Feb; 97(1):101-5. PubMed ID: 7788964
[TBL] [Abstract][Full Text] [Related]
11. Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration.
Herdlevaer I; Kråkenes T; Schubert M; Vedeler CA
Ann Clin Transl Neurol; 2020 Nov; 7(11):2231-2242. PubMed ID: 33009713
[TBL] [Abstract][Full Text] [Related]
12. Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies.
Raspotnig M; Haugen M; Thorsteinsdottir M; Stefansson I; Salvesen HB; Storstein A; Vedeler CA
Cancer Immunol Immunother; 2017 Nov; 66(11):1463-1471. PubMed ID: 28710511
[TBL] [Abstract][Full Text] [Related]
13. Expression of cerebellar degeneration-related proteins CDR2 and CDR2L in human and rat brain tissue.
Raspotnig M; Kråkenes T; Herdlevær I; Haugen M; Vedeler C
J Neuroimmunol; 2022 Jan; 362():577766. PubMed ID: 34823119
[TBL] [Abstract][Full Text] [Related]
14. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration.
Small M; Treilleux I; Couillault C; Pissaloux D; Picard G; Paindavoine S; Attignon V; Wang Q; Rogemond V; Lay S; Ray-Coquard I; Pfisterer J; Joly F; Du Bois A; Psimaras D; Bendriss-Vermare N; Caux C; Dubois B; Honnorat J; Desestret V
Acta Neuropathol; 2018 Apr; 135(4):569-579. PubMed ID: 29299667
[TBL] [Abstract][Full Text] [Related]
15. IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration.
Yshii L; Pignolet B; Mauré E; Pierau M; Brunner-Weinzierl M; Hartley O; Bauer J; Liblau R
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944244
[TBL] [Abstract][Full Text] [Related]
16. Paraneoplastic neurologic syndrome associated with gynecologic and breast malignancies.
Peter E; Honnorat J; Desestret V
Handb Clin Neurol; 2024; 200():409-417. PubMed ID: 38494293
[TBL] [Abstract][Full Text] [Related]
17. Paraneoplastic cerebellar syndromes associated with antibodies against Purkinje cells.
Schwenkenbecher P; Chacko L; Pul R; Sühs KW; Wegner F; Wurster U; Stangel M; Skripuletz T
Int J Neurosci; 2018 Aug; 128(8):721-728. PubMed ID: 29199513
[TBL] [Abstract][Full Text] [Related]
18. Paraneoplastic Cerebellar Degeneration With P/Q-VGCC vs Yo Autoantibodies.
Winklehner M; Bauer J; Endmayr V; Schwaiger C; Ricken G; Motomura M; Yoshimura S; Shintaku H; Ishikawa K; Tsuura Y; Iizuka T; Yokota T; Irioka T; Höftberger R
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 36070310
[TBL] [Abstract][Full Text] [Related]
19. Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker.
Herdlevær I; Haugen M; Mazengia K; Totland C; Vedeler C
Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33531379
[TBL] [Abstract][Full Text] [Related]
20. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss.
Tanaka M; Tanaka K; Onodera O; Tsuji S
Clin Neurol Neurosurg; 1995 Feb; 97(1):95-100. PubMed ID: 7788981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
